Analysts are more bearish on Zhejiang Huahai Pharmaceutical'...

Moomoo AI Jan 28, 2024 09:00

Analysts are more bearish on Zhejiang Huahai Pharmaceutical's future, reducing revenue and EPS estimates. The downgrade, coupled with high debt, hints at a potential business downturn.

Analysts Just Slashed Their Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) EPS Numbers

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

3415 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4820

Followers

Following

11K

Visitors